14 – 18 june 2015 • athens, greece megaron athens ... › wfsbp › 2015 › invitation › html...
TRANSCRIPT
WFSBP Congress 2015
12thWorldCongressofBiologicalPsychiatry14–18june2015•Athens,GreeceMegaron Athens International Conference Centre
organisedby: WorldFederationofSocietiesofBiologicalPsychiatry
www.wfsbp-congress.org
HostedbytheHellenicSocietyfortheAdvancementofPsychiatryandrelatedSciences
InVItAtIonProGrAmmeCallforAbstracts/ScientificProgramme
WFSBP 2015
Table of Contents
Page
1 Invitationtothe12thWorldCongressofBiologicalPsychiatry
2 AboutWFSBP
3 AbouttheWFSBPCongress2015 Congress Administration WFSBP Executive Committee International Scientific Programme Committee National Presidents Local Organizing Committee
CongressProgramme 6 Preliminary Scientific Programme Schedule 7 Preliminary Scientific Programme23 Topics24 Call for Abstracts for Free Communications and Posters25 Format Descriptions26 WFSBP Awards27 Congress Information28 General Information
WFSBPGloBAlHeAdquArterSZum Ehrenhain 3422885 Barsbüttel, GermanyPhone: +49 – 40 – 670 882 90Fax: +49 – 40 – 670 328 82 91Email: [email protected]
ConGreSSVenueMegaron Athens International Conference CentreLeoforos Vasilissis Sofias and Kokkali 1Athens 115 21, Greecewww.maicc.gr
ConGreSSAndexHIBItIonoFFICe
Hamburg OfficeHanser & Co GmbHZum Ehrenhain 34 22885 Barsbüttel, GermanyPhone: +49 – 40 – 670 88 20Fax: +49 – 40 – 670 32 83Email: [email protected]
1
WFSBP 2015
Dear Colleagues,
It is our privilege and special pleasure to invite you to the 12th World Congress of Biological Psychiatry. The World Federation of Societies of Biological Psychiatry (WFSBP) has chosen Athens for its World Congress in June 14th –18th 2015.
Following the impressive success of the 12th Congress of Biological Psychiatry in Kyoto, a real milestone in the history of WFSBP, Athens is believed to be the ideal setting to discuss the current progress in molecular biology, the development of novel drugs based upon new concepts, and the advances in modern neuroscience that will change our approach to psychiatric disorders and our attitudes towards mental health care.
Today, it is easy to envision a future where psychiatric diagnosis will be based on understanding funda-mental defects in thinking, emotional processing, and motivational systems. Psychiatry is now well positioned to take advantage of the major advances achieved in the last few decades in neurobiology and cognitive sciences and to build on them. WFSBP with its unique complementarity between basic neuroscientists and clinical psychiatrists, coming from various cultural and geographical backgrounds, is an important tool for the future of psychiatry.
During the upcoming World Congress of Biological Psychiatry, worldwide opinion leaders will share with us the recent innovations in their respective fields which impact on diagnosis, treatment and qua-lity of life of our patients. High scientific level sessions will be organized: plenary lectures, symposia, interactive workshops and debates. Young scientists are especially encouraged to present their recent findings through free communications and posters presentations.
A good number of chairpersons of WFSBP Task Forces have already committed themselves to actively participate in the scientific programme of the Athens Congress. However, we rely on the most meaning-ful participation of many colleagues from all over the world in order to make our next congress another milestone in WFSBP history. Thus, we are looking forward to welcome you in Athens, the heart of European culture and civilization, and to receive you according to the traditional Greek hospitality.
With our best personal regards
Prof. Constantin R. Soldatos Prof. Florence ThibautWFSBP President, Congress President and Chair of the InternationalChair of the Local Organizing Committee Scientific Programme Committee
Invitation to the 12th World Congress of Biological Psychiatry
Florence Thibaut
Constantin R. Soldatos
WFSBP 2015
2
Founded in 1974, the World Federation of Societies of Bi-ological Psychiatry is a non-profit world wide organisation composed of 63 National Societies of Biological Psychiatry and Individual Members representing professionals from over 70 countries.
With this multitude of countries represented in its world-wide community, the World Federation has built an inter-national network of over 4,000 opinion leaders, the majo-rity of which are key opinion-leaders in the practice of Biological Psychiatry.
WFSBPmemBerSPerContInent
As of September 2014
n Europe nAfrican Asia nMiddle Eastn South America nAustralian North America
tHePrInCIPleoBjeCtIVeSoFWFSBPAre:U To foster and encourage scientific research and advance-
ment in the field of Biological Psychiatry U To improve the quality of training spanning all the biolo-
gical psychiatry sciencesU To promote education and achieve the highest level of
knowledge and understanding within the fieldU To provide information and guidance to all institutions,
societies or individuals with an interest in biological psy-chiatry
U To establish, build, and maintain solid collaboration with international and national organisations related to biolo-gical psychiatry
Educational activities, regional, international and world con-gresses, the interactive website www.wfsbp.org, and The World Journal of Biological Psychiatry build the World Federation’s portfolio and insure its world-wide influence. The development of world-wide treatment guidelines is one of WFSBP’s main areas of international leadership.
WFSBPmemBerSPerFIeldoFACtIVIty
As of September 2014
Year after year, more and more professionals choose to join the World Federation’s Biological Psychiatry arena and en-joy its exclusive educational and networking opportunities. In the coming years WFSBP is looking forward welcoming new eminent member societies from different parts of the world.
n56,8 %
n 2,2 % n 0,4 %n4,8%
n 26 %
n 1,2 %
n8,6 %
About WfsBP
n Clinicians 88 % n Researchers 12 %
3
WFSBP 2015 WFSBP 2015
Congress AdministrAtionThe 12th World Congress of Biological Psychiatry will be organised by the World Federation of Societies of Biological Psychiatry (WFSBP)
WFsBP exeCutive CommitteePresident (2013 – 2015)Constantin R. Soldatos, Greecevice President (2013 – 2017)Tudor Udristoiu, RomaniaPast President (2013 – 2015)Florence Thibaut, FrancePresident elect (2013 – 2015)Masatoshi Takeda, Japansecretary (2013 – 2017)Lakshmi N. Yatham, Canadatreasurer (2013 – 2017)Martin Hatzinger, Switzerlandvice secretary (2013 – 2017)Ladislav Hosak, Czech Republicvice treasurer (2013 – 2017)Victoria Valdez, Ecuador
internAtionAl sCientiFiC ProgrAmme Committee (isPC)Florence Thibaut, France ChairPeter Falkai, Germany Co-ChairShigenobu Kanba, Japan Co-ChairLakshmi N. Yatham, Canada Co-ChairMichel Bourin, France Secretary
members of isPCC. A. Altamura, Italy*M. Bauer, GermanyA. Benyamina, France*M. Berk, Australia*J. Bobes, SpainC. L. Bowden, USAJ. Bradford, CanadaP. Brambilla, ItalyM. Bras, CroatiaM. S. Buchsbaum, USAD. Castle, AustraliaE. Ceskova, Czech RepublicJ. Ciprian-Ollivier, ArgentinaP. Cosyns, BelgiumP. Courtet, France*B. Dean, Australia
K. Fountoulakis, GreeceS. Frangou, UKW. Gaebel, GermanyF. Duarte Garcia, BrazilW. F. Gattaz, Brazil*M. George, USAB. Glenthoj, DenmarkP. Gorwood, FranceG. M. Goodwin, UKA. Grace, USAH. Grunze, UKA. Halaris, USAA. Hasan, Germany*C. Hiemke, GermanyE. Holsboer-Trachsler,SwitzerlandW. G. Honer, CanadaR. Kahn, The NetherlandsS. Kasper, AustriaT. Kato, JapanJ. Kane, USAJ. Kennedy, CanadaH. R. Kranzler, USA R. Lanzenberger, AustriaV. Larach, ChileA. Lopez Mato, ArgentinaC. Lyketsos, USAR. McCarley, USAM. Maes, BelgiumH. Mayberg, USAA. Kant Mital, IndiaE. Mohan Das, IndiaN. Müller, GermanyT. Murai, JapanCh. Pantelis, AustraliaG. Papadimitriou, GreeceT. Paparrigopoulos, Greece*O. Pogarell, GemanyR. Post, USA*M. Rapaport, USAM.S. Reddy, India*P. Riederer, GermanyR. Rupprecht, GermanyT. Saito, JapanM. Sarchiapone, ItalyN. Sartorius, SwitzerlandA. Schmitt, GermanyT. G. Schulze, Germany*
About the wfsbp Congress 2015
* Special correspondents of ISC Core Group
4
WFSBP 2015 WFSBP 2015
About the wfsbp Congress 2015
S. Seedat, South Africa*A. Seretti, ItalyE. Serfaty, ArgentinaL. Siever, USAN. Stefanis, Greece*J. Steiner, GermanyT. Suhara, JapanM.Takeda, JapanJ. Tellez-Vargas, ColombiaN. Venizelos, SwedenJ. Waddington, IrelandA. Weinstein IsraelP. Whybrow, USAY. Zervas, Greece*
Consultants to the ISPCG. Alexopoulos, USAC. Arango, Spain*E. Baca Garcia, SpainE. Belfort, VenezuelaA. Bozkurt, CyprusN. Boutros, USAP. Boyer, FranceA. Burns, UKR. Castilla-Puentes, USAM. Cetkovich-Bakmas, ArgentinaY. Hwa Chou, TaiwanH. Correa, BrazilJ. Costa e Silva, BrazilP. Cosyns, BelgiumJ. de Buitelaar, The NetherlandsM. Dierick, BelgiumB. Dubois, FranceP. Gejman, USAA. Germanavicious, LithuaniaA. H. Glassman, USAD. Gorelick, USAG. Hajak, GermanyS. Heckers, USA*Y. Hirayasu, JapanE. Hollander, USAJ. Horacek, Czech RepublicA. Jablensky, AustraliaC. Katona, UKW. Kaye, USAL. Konopka, USA
C. Krieg, GermanyT. Kudo, JapanJ. Soo Kwon, Korea*S. Lamy, FranceM. Leboyer, France M. Lejoyeux, FranceM. So Lee, KoreaB. Leonard, IrelandY. Levkovitz, IsraelP. Mc Gorry, AustraliaP. Mc Guire, UKA. Malafosse, SwitzerlandJ.-L. Martinot, FranceH. Y. Meltzer, USAA. Meyer-Lindenberg, GermanyZ. Nahas, LebanonD. Nutt, UKJ. Ospina-Duque, ColombiaN. Ozaki, JapanG. Parker, AustraliaL. Pezewas, AustriaS. G. Potkin, USAM. Rapaport, USAE. Richelson, USAJ. Rybakowski, PolandD. Rujescu, GermanyH. Sackeim, USAP. Salgado Pineda, SpainT. Schläpfer, GermanyL. Schneider, USAC. Schulz, USAE. Seifritz, SwitzerlandW. W. Shen, TaiwanL. Siever, USAD. St. Clair, UKM. Taleb, France/AlgeriaT. Taneli, USAJ. Treasure, UKN. A. Uranova, RussiaJ. Van Os, The NetherlandsD. Velakoulis, AustraliaE. Vieta, SpainX. Yu, China*M. Zanarini, USAJ. Zohar, Israel l
* Special correspondents of ISC Core Group
5
WFSBP 2015
About the WfsBP Congress 2015
nAtIonAlPreSIdentSA. Rivetti, ArgentinaA. Boyajyan, ArmeniaJ. Marksteiner, AustriaS. Claes, BelgiumN. D. Noya-Tapia, BoliviaA. Kucukalic, Bosnia-HerzegovinaP. Abreu, BrazilO. Atanasova Mikova- Demireva, BulgariaR. R. Lam, CanadaP. Rebolledo, ChileJ. Franco, ColumbiaR. Castro, Costa RicaM. Jakovljevic, CroatiaL. Hosak, Czech RepublicG. Wegener, DenmarkF. Solis de Mendez, Dominican RepublicV. Valdez de Vuibert, EcuadorA. Okasha, EgyptM. Meija Pena, El SalvadorJ. Harro, EstoniaP. Courtet, FranceA. Heinz, GermanyC. R. Soldatos, GreeceH. Soto Chavez, GuatemalaM. Aguilar Lopez, HondurasS.-W. Tang, Hong KongC. Banki, HungaryR. Nagpal, IndiaA. J. Tanra, IndonesiaG. Zalsman, Israel
M. Maj, ItalyT. Nishikawa, JapanM. Assimov, KazakhstanC. Uk Lee, KoreaB. Kupca, LatviaC. Baddoura, LibanonB. Stefanovski, MacedoniaS. Krishnaswamy, MalaysiaD. Moussaoui, MaroccoR. Castro-Roman, MexicoH. Lovdahl, NorwayM. Amin, PakistanG. Da Costa, PanamaL. Villalba, ParaguayE. Galli, PeruA. Wichniak, PolandJ. Relvas, PortugalT. Udristoiu, RomaniaN. Noznanoo, RussiaN. Maric Bojovic, SerbiaL. Vavrusova, SlovakiaS. Seedat, South AfricaM. Bernardo, SpainM. Msghina, SwedenM. Hatzinger, SwitzerlandCh.-Y. Liu, TaiwanP. Udomratn, ThailandB. Taneli, TurkeyA. V. Kalueff, UkraineA. D’Ottone, UruguayJ. Ibáñez-Domínguez, Venezuela
loCAlorGAnIZInGCommIttee(loC)Chair: C. R. SoldatosHonorary Chair: C. Stefanis
GeneralmembersD. AnagnostopoulosC. AndroutsosE. AngelopoulosN. BergiannakiP. BitsiosG. DiakogiannisD. DikeosA. DouzenisC. FokasK. FountoulakisG. GaryfalosA. GenaF. GourzisJ. HatzimanolisS. KaprinisG. KarantanosA. KarkaniasG. KolaitisS. KotsopoulosA. KoumoulaH. LazaratouM. Liakopoulou
M. MallioriV. MavreasG. MoussasG. NimatoudisM. PanagiotakopoulouG. PapadimitriouG. PapageorgiouC. PapageorgiouT. PaparrigopoulosE. PatsourisA. PolitisC. PsarrosP. SakkasM. SamakouriN. SmyrnisP. SkapinakisN. StefanisC. TouloumisE. VarsouA. VgontzasY. ZervasN. Zilikis
HonorarymembersN. AngelopoulosS. BeratisA. BotsisG. ChristodoulouI. GiouzepasC. IerodiakonouG. KaprinisA. KaravatosV. KontaxakisA. Liakos
I. LiappasM. LivaditisM. MadianosA. MailisY. PapakostasA. RabavilasG. TrikkasJ. TsiantisE. TzebelikosN. Vaidakis
WFSBP 2015
6
Preliminary scientific Programme schedule
technicalexhibitiontimes
Monday, 15 June 2015 09:00 – 17:00
Tuesday, 16 June 2015 09:00 – 17:00
Wednesday, 17 June 2015 09:00 – 17:00
Posterexhibitiontimes
Monday, 15 June 2015 09:00 – 17:00
Tuesday, 16 June 2015 09:00 – 17:00
Wednesday, 17 June 2015 09:00 – 17:00
Thursday, 18 June 2015 09:00 – 17:00
registrationCounter–openinghours
Sunday, 14 June 2015 12:00 – 19:00
Monday, 15 June 2015 07:30 – 18:30
Tuesday, 16 June 2015 08:00 – 18:30
Wednesday, 17 June 2015 08:00 – 18:30
Thursday, 18 June 2015 08:00 – 17:00
Sunday,14june monday,15june tuesday,16june Wednesday,17june thursday,18june
8:30
–
10:00
Symposia, Free Communication
Symposia, Free Communication
Symposia, Free Communication
Symposia, Free Communication
exH
IBIt
Ion
/Po
Ster
exH
IBIt
Ion
and
Gu
Ided
Po
Ster
to
ur
S
exH
IBIt
Ion
/Po
Ster
exH
IBIt
Ion
and
Gu
Ided
Po
Ster
to
ur
S
exH
IBIt
Ion
/Po
Ster
exH
IBIt
Ion
and
Gu
Ided
Po
Ster
to
ur
S
10:00 –
10:45Plenary Lecture Plenary Lecture Plenary Lecture Plenary Lecture
11:00
–
12:30
Symposia, Debates, Treatment Guidelines
Symposia, Debates, Treatment Guidelines
Symposia, Debates, Treatment Guidelines
Symposia, Round Table, Treatment Guidelines
reG
IStr
AtIo
n1
2:00
–1
9:00
13:15
–
14:45
Industry-Sponsored Sessions
Industry-Sponsored Sessions
Industry-Sponsored Sessions
Industry-Sponsored Sessions
15:00
–
16:30
Symposia, Treatment Guidelines
Symposia, Treatment Guidelines
Symposia, Treatment Guidelines
Symposia, Treatment Guidelines
16:30
–
18:00
Workshops,Free Communication
Workshops,Free Communication
Workshops,Free Communication
Closing Ceremony
from 17:00
Opening Ceremony,and Receptionand Networking Event
18:15
–
19:45
Industry-Sponsored Sessions
Industry-Sponsored Sessions
Industry-Sponsored Sessions
7
WFSBP 2015
Plenary Lecture, Debates, WfsBP Treatment Guidelines / Preliminary scientific Programme
oPenInGleCture
riskandresilienceforpsychosisandautism:dodevel-opmentalbrainchangesmatter?Chair: ConstantinR.Soldatos,GreeceSpeaker: ChristosPantelis,Australia/Greece
PlenAryleCtureS
dSm,ICdandrdocandthefutureofpsychiatricdi-agnosisChair: LakshmiYatham,CanadaSpeaker: MarioMaj,Italy
offlabeluseinpsychiatryChair: FlorenceThibaut,FranceSpeaker: GuyGoodwin,UK
neuropsychiatric syndromes of later life: ImplicationsforthestudyandtreatmentofmajorpsychiatricdiseasesChair: MasatoshiTakeda,JapanSpeaker: ConstantineLyketsos,USA/Greece
neurobiologicaloffearandanxietyanditsclinicalim-plicationsChair: MartinHatzinger,SwitzerlandSpeker: KerryRessler,USA
deBAteS
Isithelpfultotreatanxietypharmacologically?Proponent: MichelBourin,FranceOpponent: BorwinBandelow,Germany
Behavioraladdictions–normalityordeviance?Proponent: MarcPotenza,USAOpponent: PierVincenzoPiazza,France
Arechildrenovermedicated?Proponent: RobertPost,USAOpponent: TomInsel,USA
roundtABle
Isthereroomfornewpsychotropicdrugs?
WFSBPtreAtmentGuIdelIneS
taskForceonBipolardisordersImprovinglongitudinaltreatmentforbipolardisordersincludingmixedstatesguidelinesChair: SiegfriedKasper,AustriaPresenters:HeinzGrunze,Germany,EduardVieta,Spain, CharlesBowden,USA
taskForceonGeneticsChair: DanRujescu,GermanyCo-Chair: MickC.O´Donovan,UnitedKingdom
Genomicsofschizophrenia:resultsfromthelargestasso-ciationstudysofarMickC.O´Donovan,UnitedKingdom
thegeneticsofschizophrenia:BacktofamilystudiesLynnDelisi,USA
Geneticsofintermediatephenotypes:FocusoncognitionDanRujescu,Germany
ClinicalapplicationofpsychiatricpharmacogenetictestingJamesKennedy,Canada
taskForceonnosologyPsychopathology–past,presentandfutureChair: WolfgangGaebel,GermanyCo-Chair: VeronicaLarach,Chile
Psychopathologyandneuroscience:AmodularityapproachWolfgangGaebel,Germany
Afterjaspers,whatelse?MichaelMusalek,Austria
Gene-environmentinteractionandpsychopathologyGeorgeN.Papadimitriou,Greece
teachingpsychopathologytodayVeronicaLarach,Chile
taskForceonParaphiliasParaphiliatreatmentforadultsandadolescentsChair: FlorenceThibaut,FranceCo-Chair: PerBriken,Germany
theproposeddiagnosticcriteriaofparaphilicdisordersforICd-11PerBriken,Germany
WFSBPtreatementguidelinesonparaphiliasJohnM.W.Bradford,Canada
ethicalconsiderationsPaulCosyns,Belgium
Guidelinesondepression:GlobalizationorlocalizationChair: MichaelBauer,GermanyCo-Chair: RaymondW.Lam,Canada
WFSBPguidelinesforunipolardepressionEmanuelSeverus,Germany
GuidelinesformajordepressivedisorderinKorea
KangSeobOh,RepublicofKorea
Global guidelines for psychiatrists, local guidelines forgeneralpractitioners–mddguidelinesintaiwanChia-YihLiu,Taiwan
WFSBP 2015
8
Preliminary scientific Programme / symposia
CAnmAtdepressionguidelines:thenextgenerationofprogressRaymondW.Lam,Canada
taskForceonSchizophreniaChair: PeterFalkai,GermanyCo-Chair: AlkomietHasan,Germany
WFSBPGuidelinesontheacutetreatmentofschizophreniaAlkomietHasan,Germany
WFSBPGuidelinesonthelong-termtreatmentofschizo-phreniaThomasWobrock,Germany
taskForceonAddictivedisordersPresenters:MichaelSoyka,Germany KarlMann,Germany
SymPoSIA
Addictive disorders
Alcohol,nicotineandmetamphetamineaddiction,progressatbasicandclinicalfrontsChair: YousefTizabi,USACo-Chair: RosarioMoratalla,Spain
Alcoholandnicotineinteractions:Implicationsfordrinking-smokingco-morbidityYousefTizabi,USA
metamphetaminedamageofdopaminergicneuronsandmotorconsequencesRosarioMoratalla,Spain
Imaging and clinical intervention in metamphetamineaddictionHamedEkhtiari,Iran
Clinicalinterventionindrinking-smokingco-morbidityBoSöderpalm,Sweden
Behavioraladdictions:diagnosis,co-morbidityandneurobiologyChair: AvivWeinstein,IsraelCo-Chair: MarcPotenza,USA
Hypersexuality:obsessionoraddiction?FlorenceThibaut,France
A personal status, legal, economic and psychologicalcomparisonoftypesofadultmalegamblersPinhasDannon,Israel
doesfoodaddictionexist?MarcPotenza,USA
exerciseaddiction–brainandbehaviorAvivWeinstein,Israel
metabotropicglutamatereceptorsindrugandalcoholdependenceChair: AthinaMarkou,USACo-Chair: MarcusMunafo,UnitedKingdom
mGlur and mGlur7 activation, and mGlur5 blockademodulateconditionedbehavioralandneurochemicalef-fectsofpsychostimulantsinratsAthinaMarkou,USA
rescueofinfralimbicmGlur2deficitrestorescontrolofdrug seeking in alcohol dependent rats consistent withdecreased mGlur2 function in alcoholic patients andalcohol-dependentratsRainerSpanagel,Germany
reductioninmGlur5receptorbindinginhumansmok-ersandex-smokersdeterminedbypositronemissionto-mographyGregorHasler,Switzerland
Cognitive attentional bias for drug- and alcohol-relatedcues:studiesinnicotineandalcoholdependenthumansubjectsMarcusMunafo,UnitedKingdom
newchallengesinpsychoactivesubstancesandaddictionstreatmentsChair: AmineBenyamina,FranceCo-Chair: FrancoTagliaro,Italy
Clinicalefficacyofhighdoseofbaclofeninreducingalco-holconsumptionPhilippeJaury,France
Impact of chronic cannabinoid adolescent exposure onprefrontalstructureandfunctionThereseJay,France
new challenges for forensic toxicology from the “newPsychoactiveSubstances”FrancoTagliaro,Italy
Acutehumaneffectsofsyntheticcannabinoids:Howaretheyrelatedtocannabinoidreceptorligandproperties?DavidGorelick,USA
AntidepressAnts: BAsic / clinicAl
novelmechanismsofactionofantidepressanttreatmentChair: RainerRupprecht,GermanyCo-Chair: MarkRasenick,USA
lipidraftsandsignallingcascadesastargetsforantide-pressantsRainerRupprecht,Germany
9
WFSBP 2015
symposia / Preliminary scientific Programme
theroleoflipidraftsforantidepressantmediatedG-pro-teinsignallingMarkRasenick,USA
theroleofp-glycoprotein for theeffectsofantidepres-santsonHPAaxisCarminePariante,UnitedKingdom
thecytoskeletonasatargetforantidepressantsMassimilianoBianchi,Ireland
Antipsychotics: BAsic / clinicAl
AbetteruseofantipsychoticstoimprovetheprognosisofschizophreniaChair: MiquelBernardo,SpainCo-Chair: PhilippeCourtet,France
Pharmacogeneticofantipsychotics,asatooltoimproveresponsetocognitiveremediationRobertoCavallaro,Italy
Advantages of long-acting injectable antipsychotics (ineverydaylife)DieterNaber,Germany
relapse prevention and long-acting injectable antipsy-choticsinearlyphasesofschizophreniaEduardParellada,Spain
Interestofguidelinestoimprovetheeverydayuseofanti-psychotics:methodological,andimplementationaspectsPierre-MichelLlorca,France
d-aminoacidsandd-aminoacidoxidase(dAAo)basedmodulationofnmdArneurotransmission:diagnosticandtherapeuticimplicationsChair: KenjiHashimoto,JapanCo-Chair: Hsien-YuanLane,Taiwan
Preclinicalstudyofd-serinesignalinginschizophreniaKenjiHashimoto,Japan
d-aspartate based modulation of nmdAr neurotrans-mission:ClinicalimplicationAlessandroUsiello,Italy
d-amino acid oxidase (dAAo) based modulation ofnmdArneurotransmission:therapeuticimplicationHsien-YuanLane,Taiwan
d-amino acid oxidase (dAAo) activator levels in peri-pheralblood:diagnosticimplicationChieh-HsinLin,Taiwan
Anxiety disorders: BAsic / clinicAl
Anxietydisorders–clinicalandbiologicalmarkersindiagnosisandtreatmentChair: BorwinBandelow,GermanyCo-Chair: KatharinaDomschke,Germany
Patho-andtherapy-geneticsofanxietydisordersKatharinaDomschke,Germany
Childhoodanxietyasaprecursorofotherpsychiatricdis-ordersinadulthoodChristerAllgulander,Sweden
meta-analysisofalltreatmentsforanxietydisordersBorwinBandelow,Germany
theneedfornewtargetsinanxietydisorders:Fromneu-robiologytotreatmentNicJ.A.vanderWee,Germany
Sexdifferencesintheneurobiologyoffearandanxiety:AtranslationalapproachChair: MohammedMilad,USACo-Chair: RebeccaShansky,USA
Sex-specific behavioral and neuroanatomical profiles ofhigh-fearphenotypesRebeccaShansky,USA
SexdifferencesintheeffectsofstressonlearningLisaMaeng,USA
Cortisol and context-dependent extinction learning:differencesbetweenmenandwomenOliverWolf,Germany
Influenceofestrogenontheneuralcorrelatesoffearex-tinctionacrossspeciesKelimerLebron-Milad,USA
BipolAr disorders: BAsic / clinicAl
BiologicalandclinicalaspectsofmooddisorderswithpsychoticfeaturesChair: ThomasSchlaepfer,GermanyCo-Chair: PeterFalkai,Germany
BiomarkersassociatedwithpsychoticsymptomsinmajordepressionAlanSchatzberg,USA
VisualizationtechniquesandpsychoticpatternsPeterFalkai,Germany
Immunological and neuroimaging patterns associatedwithpsychoticdimensioninbipolardisorderCarloAltamura,Italy
PharmacologicaltreatmentofpsychoticmooddisordersHeinzGrunze,UnitedKingdom
WFSBP 2015
10
Preliminary scientific Programme / symposia
CAnmAtclinicalguidelinesforbipolardisorders2013:theevolutioncontinuesChair: LakshmiYatham,CanadaCo-Chair: RoumenMilev,Canada
Guidelines for clinical practice in bipolar disorders?overviewofthefieldKonstantinosFountoulakis,Greece
CAnmAt’s role indevelopingand implementingguide-linesforclinicalpracticeSagarParikh,Canada
CAnmAt/ISBdguidelines:2013updateRoumenMilev,Canada
thefutureofCAnmAt/ISBdguidelinesLakshmiYatham,Canada
majorcontroversiesforthetreatmentofbipolardisordersChair: GustavoVazquez,ArgentinaCo-Chair: EduardVieta,Spain
noveltreatmentsforbipolardisordersEduardVieta,Spain
optimal duration of atypical antipsychotic therapy formaintenancetreatmentLakshmiYatham,Canada
neuroprotectivepotentialofmoodstabilizersMichaelBerk,Australia
useofantidepressantsinbipolardisordersGustavoVazquez,Argentina
childhood & Adolescent disorders: BAsic / clinicAl
AdvancesinchildpsychiatryresearchChair: JosephBiederman,USACo-Chair: GaganJoshi,USA
Areautistictraitsclinicallymeaningful?JosephBiederman,USA
resting state functional connectivity analysis of socialnetworksinadolescentsandyoungadultswithhigh-func-tioningautismspectrumdisorderGaganJoshi,USA
resting-state functional connectivity in a longitudinalstudyofAdHdchildrengrownupMaiUchida,USA
memantineinthetreatmentofadultswithAdHdThomasSpencer,USA
majorpsychopathologyduringadolescenceandearlyadulthood:thedynamicdevelopmentalinterplaybetweenprotectiveandriskfactorsChair: PaoloBrambilla,ItalyCo-Chair: JairC.Soares,USA
Grin2b mediates susceptibility to affective problems inchildrenandadolescentsMariaNobile,Italy
developmentimagingandcognitivemarkersofpediatricParkinson’sdiseaseJairC.Soares,USA
Functionalimagingmarkersofpsychosisduringadoles-cenceVaibhavDiwadkar,USA
riskandprotectivefactorsforpsychopathologydetectedinthemannheimatriskStudy(mArS)ManfredLaucht,Germany
oxytocinandsocialcognition:FromsocialattachmentandrewardtonoveltreatmentsforautismChair: LarryYoung,USACo-Chair: AdamGuastella,Australia
oxytocin and social attachment: Implications for noveltherapiesforautismLarryYoung,USA
Interactions of oxytocin and serotonin in the striatummediatesocialrewardGulDolen,USA
Variation in the oxytocin receptor gene predicts facerecognitionabilitiesinfamilieswithanautisticchildDavidSkuse,UnitedKingdom
oxytocin therapies to treat core social impairments inautism:ClinicaltreatmenttrialsintoddlersandyouthAdamGuastella,Australia
cognitive neuroscience
Convergentapproachestoimpulsivity:theroleofnoradrenalineinAdHdandParkinson’sdiseaseChair: UlrichMüller,UnitedKingdomCo-Chair: AngieKehagia,UnitedKingdom
ChemicalneuroanatomyofAdHdandParkinson’sdis-ease–similaritiesanddifferencesManfredGerlach,Germany
PetimagingofthenoradrenergicsysteminAdHdandParkinson’sdiseaseRupertLanzenberger,Austria
11
WFSBP 2015
symposia / Preliminary scientific Programme
ImpulsecontroldisordersanddepressioninParkinson’sdisease–isthereanoradrenergiclink?LauraMarsh,USA
noradrenergicmodulationof impulsivity inParkinson’sdiseaseAngieKehagia,UnitedKingdom
dementiA: BAsic / clinicAl
ClinicalneurochemistryintheearlydiagnosisofdementiadisordersChair: PiotrLewczuk,GermanyCo-Chair: HenrikZetterberg,Sweden
Current status and new developments for Alzheimer’sdiseasebiomarkersKajBlennow,Sweden
diagnosticapproachesinfrontotemporallobardegener-ation(Ftld)MarkusOtto,Germany
Biomarkers for thediagnosis andprogressionofmotorandpremotorParkinson’sdiseaseBritMollenhauer,Germany
Blood biomarkers for neurodegenerative disorders –feasibleortoomuchofachallenge?HenrikZetterberg,Sweden
depression: BAsic / clinicAl
Identifyingbiomarkersoftreatmentoutcomeindepression:CanadiannetworkforbiomarkerintegrationindepressionChair: SidneyKennedy,CanadaCo-Chair: GregorHasler,Switzerland
BiomarkersandthefutureoftreatmentindepressionMadhukarTrivedi,USA
discoveringendophenotypesinmajordepressionGregorHasler,Switzerland
Genese: Pharmacological response to antidepressanttreatmentinthegeneralpopulationtreatedfordepressionNicolasRamoz,France
CAnBInd–updateontheprogresssofarSidneyKennedy,Canada
Inflammationandmitochondrialdysfunction:relevancetodepressionChair: MichaelBerk,AustraliaCo-Chair: OliviaDean,Australia
towardsdevelopmentofbiomarkersforpsychiatry:rele-vancetomitochondrialdysfunctionAnaCristinaAndreazza,Canada
theroleofinflammationinthebiologyandaetiologyofdepressionMichaelMaes,Thailand
targetingmitochondrialdysfunctionandoxidativestresstolowertheburdenofmooddisorders:Stateoftheevi-denceandfuturedirectionsPedroMagalhaes,Brazil
noveltherapiesfordepression:Anti-inflammatorytreat-mentsOliviaDean,Australia
molecularandgeneticsubstratesunderpinningdiagnosisofmajordepressionChair: YogeshDwivedi,USACo-Chair: DanRujescu,Germany
micrornA-mediated reorganization of gene expressionnetworksanditsroleindepressionpathogenesisYogeshDwivedi,USA
neurotrophic-andGABA-relatedcorticolimbicpathologyindepressionEtienneSibille,USA
dnAmethylationandchromatinremodelingincomplexphenotypeofmajordepressionGustavoTurecki,Canada
neuroticism:roleinnegativemoodstatesandinternaliz-ingdepressiveconditionsDanRujescu,Germany
novelbiomarkersinmooddisorders:opportunitiesfortranslationintoclinicalpracticeChair: BernhardBaune,AustraliaCo-Chair: KenjiHashimoto,Japan
A translational perspective on the neurotrophin hypo-thesisofdepressionMarcL.Molendijk,TheNetherlands
BdnF and its precursor proBdnF as biomarkers formooddisordersKenjiHashimoto,Japan
ApoptosisasnewbiomarkerformooddisordersYakupAlbay,Turkey
GeneticandserumimmunebiomarkersindepressionBernhardBaune,Australia
WFSBP 2015
12
Preliminary scientific Programme / symposia
Sleepandneuroplasticity:ClinicalimplicationsfordepressionChair: EdithHolsboer-Trachsler,SwitzerlandCo-Chair: AxelSteiger,Germany
AnimalmodelsofdisruptedsleepTarjaPorkka-Heiskanen,Finland
SleepandsynapticdysfunctionindepressionAnneEckert,Switzerland
SleepaspredictorofemotionalregulationinchildrenMartinHatzinger,Switzerland
Sleep-eeGderivedbiomarkersofdepressionAxelSteiger,Germany
epidemiology
latencytopharmacologicaltreatmentsinpsychiatricdisorders:epidemiological,biologicalandclinicalaspectsChair: CarloAltamura,ItalyCo-Chair: MarionLeboyer,France
duration of untreated bipolar disorder: missed oppor-tunitiesforoptimaltreatmentMarionLeboyer,France
Assessinglatencytopharmacologicaltreatmentsinpsy-chiatricdisorders:differencesbetweenaffectiveandpsy-choticdisordersBernardoDell´Osso,Italy
BiologicalfindingsinrelationtountreatedschizophreniaJariTiihonen,Finland
theeffectofprolongeddurationofuntreateddepressiononantidepressanttreatmentoutcomeLarsVedelKessing,Denmark
genetics
AdvancesingeneticsofaffectivedisordersChair: GeorgeN.Papadimitriou,Greece
updateongeneticsofaffectivedisordersDimitrisDikeos,Greece
PharmacogeneticsofantidepressantsAlessandroSerretti,Italy
organizationandadministrationofamultinationalpro-jectonpharmacogeneticsDanielSurrey,Belgium
overviewofthefieldandcriticalappraisalsThomasSchulze,Germany
epigeneticacquisitionsinmooddisorders:ImplicationforpathophysiologyandtreatmentChair: CarloAltamura,ItalyCo-Chair: TomasEkstrom,Sweden
role of epigenetic modulation in psychiatric disorders:thestateofartTomasEkstrom,Sweden
epigeneticregulationofBdnFgeneinbipolarvs.unipo-lardepressivedisordersBernardoDell´Osso,Italy
epigeneticmechanismsandendocannabinoidsignaling:Aputativetreatmentforpsychiatricdisorders?MauroMaccarone,Italy
PossiblemechanismsandbiologicaltargetsforepigeneticmodulationinpsychiatricdisordersClaudioD´Addario,Italy
Immunogenetics:exploringnewterritoryinschizophreniaChair: JamesKennedy,CanadaCo-Chair: JenniePouget,Canada
Hypothesis-drivengenome-wideassociationstudyidenti-fiesimmunegenesassociatedwithschizophreniaJenniePouget,Canada
new data to investigate an old epidemiological puzzle:the negative association between schizophrenia andrheumatoidarthritisNaomiWray,Australia
extremestructuralvariationofthehumanHlAlocusanditsrelationshiptoschizophreniariskStevenMcCarroll,USA
themicrobiome:themissinglinkinthepathogenesisofschizophreniaRobertYolken,USA
moleculAr neuroBiology
BiomarkersinpsychiatricdisordersChair: PeterRiederer,GermanyCo-Chair: FlorenceThibaut,France
BiomarkersinschizophreniaPeterFalkai,Germany
BiomarkersinAdHdEdnaGrünblatt,Switzerland
BiomarkersinalcoholismToshikazuSaito,Japan
BiomarkersinAlzheimer‘sdiseaseMarkusSchwarz,Germany
13
WFSBP 2015
symposia / Preliminary scientific Programme
Glutamatergicmechanismsinschizophrenia:FromketaminetogeneticmodelsChair: PeterGass,GermanyCo-Chair: KazutoshiNakazawa,USA
Ketaminereversal:towardsempiricaldiscoveryofanti-psychoticswithneuroimagingPhilipCorlett,USA
expressionanalysisofanmdAmK-801ratmodelidenti-fiesnovelcandidategenesforschizophreniaDanRujescu,Germany
mechanismsofneuronalsynchronydeficits innmdAr-hypofunction-mediatedschizophreniamousemodelKazutoshiNakazawa,USA
Inducible genetic mouse models to study the onset ofschizophreniaduringlateadolescenceDragosInta,Germany
neuron-Gliainteractionsandneuropsychiatricdisease:ImplicationsfornoveltherapeuticsChair: ThomasSedlak,USACo-Chair: Jean-PierreMothet,France
d-serine and glycine in gliotransmission: Synaptic andextra-synaptictargetsJean-PierreMothet,France
neuron-astrocyteinteractions–acriticaljuncturewheregene-environmentinteractionsincreaseriskofpsychiatricdiseaseMikhailPletnikov,USA
relation of inflammatory cytokines, astrogliosis mark-ersandprefrontalgreymattervolumeinschizophreniasubgroupsVibekeCatts,Australia
Interplay of neurons and glia for glutamate and gluta-thionecycling–newavenuestotargetexcitatoryneuro-transmissionabnormalitiesinneuropsychiatricdisordersThomasSedlak,USA
neuropAthology
understandingpsychiatricdisorders:recentadvancesinpostmortemresearchChair: BrianDean,AustraliaCo-Chair: ElizabethScarr,Australia
StructuralandmolecularalterationsofthehippocampusinschizophreniaPeterFalkai,Germany
rolesforimmune-regulatedgenesandneurotransmitterreceptorsinthepathophysiologyofpsychiatricdisordersBrianDean,Australia
thesyndromeofschizophrenia:Progresstowardspoten-tialbiomarkersElizabethScarr,Australia
Autophagyasfuturetreatmenttargetforschizophrenia:lessonsfromactivity-dependentneuroprotectiveproteinIllanaGozes,Israel
neuroimAging: genetic, FunctionAl, structurAl
Biologicaloverlapsbetweenschizophreniaandautismspectrumdisorders:neuroimagingandneurophysiologyChair: SergeMitelman,USACo-Chair: MonteBuchsbaum,USA
neural correlates in autism spectrum disorders andschizophreniaJunkoFukushima,Japan
Positron emission tomography in patients with schizo-phreniaandautismspectrumdisordersMarie-CécileBralet,France
Srgap3-/mice present a neurodevelopmental disorderwithschizophrenia-relatedandautism-relatedintermedi-atephenotypes:ImplicationsforpsychiatryRobertWaltereit,Germany
mrIanddiffusiontensorimagingassessmentofpatientswithschizophreniaandautisticdisorderMonteBuchsbaum,USA
BrainimagingandtreatmentreponseChair: SiegfriedKasper,AustriaCo-Chair: LarsFarde,Sweden
multimodalimagingandtreatmentresponseindepressionSiegfriedKasper,Austria
targetsfordeepbrainstimulationindepressionThomasSchlaepfer,Germany
d2-receptoroccupancyandtreatmentreponseinschizo-phreniarevisitedLarsFarde,Sweden
Imagingoftheglutamatergicneuroreceptors,anewtarget?ErichSeifritz,Switzerland
WFSBP 2015
14
Preliminary scientific Programme / symposia
developmentofbiomarkersforneuropsychiatricdisorders:State-of-the-artandchallengesaheadChair: NikolaosKoutsouleris,GermanyCo-Chair: ChristosDavatzikos,USA
neurocognitiveandimaging-basedmodelofnormalandabnormalbrainmaturationfromchildhoodtoearlyadult-hoodTedSatterthwaite,Germany
machinelearningbiomarkersforindividualizedoutcomepredictioninfunctionalpsychosesLenaPalaniyappan,UnitedKingdom
Geneticmarkersofautism-spectrumdisordersChristosPantelis,Australia
diagnosticandprognosticimagingmarkersinneurode-generativedisordersStefanKlöppel,Germany
neuroimagingandriskforschizophreniaChair: LynnDelisi,USACo-Chair: MarekKubicki,USA
neuroimaginginpeopleatultrahighriskforpsychosisPhilipMcGuire,UnitedKingdom
mechanismsunderlyingbrainchangesinearlypsychosisChristosPantelis,Australia
earlychildhoodbraindevelopmentinchildrenatriskforschizophreniaJohnGilmore,USA
newwhitematterbiomarkersofschizophreniariskMarekKubicki,USA
neurophysiology
neuraloscillations:translationalresearchinpsychiatryChair: ToshiakiOnitsuka,JapanCo-Chair: RobertMcCarley,USA
neuraloscillations:optogeneticstudiesinmiceRobertMcCarley,USA
Findingsofauditorysteady-stateresponsesinpsychiatricdisordersToshiakiOnitsuka,Japan
neuraldynamicswithsimultaneouseeGandfmrImea-surementHiroakiMizuhara,Japan
nmdA-r hypofunctioning and dysregulated high-fre-quencyoscillationsinschizophreniaPeterUhlhaas,UnitedKingdom
SerotoninandneuroplasticityChair: RupertLanzenberger,AustriaCo-Chair: ChristophKraus,Austria
effectsofserotoninonneurostimulationinducedcorticalplasticityWalterPaulus,Austria
SerotoninandneuroplasticityEeroCastren,Finland
Serotonin and neuroplasticity investigated in vivo withneuroimagingChristophKraus,Austria
neuralplasticityintheetiologyandtherapyofpsychiatricdisordersTiloKircher,Germany
pAin: BAsic / clinicAl
resolvingthemissinglinkbetweenphysicalandmentalpain:Basic,clinical,andtranslationalapproachesChair: ShigenobuKanba,JapanCo-Chair: TimSalomons,UnitedKingdom
ComorbidityofpsychiatricdisordersinchronicpainRyotaHashimoto,Japan
microgliaasapainmaker inneuropathicpain:rodentstudiesMakotoTsuda,Japan
therapeutic and neuroimaging approaches to physicalandmentalpainTimSalomons,UnitedKingdom
microgliaasapossiblekeyplayer tobindphysicalandpsychologicalpain:translationalapproachShigenobuKanba,Japan
15
WFSBP 2015
symposia / Preliminary scientific Programme
phArmAcology
Crossspeciesstudiesofpsychedelicdrugs–relevancetopsychiatricdisordersChair: FranzVollenweider,SwitzerlandCo-Chair: MarkA.Geyer,USA
BehavioralandpharmacologicalstudiesofpsychedelicsinanimalsMarkA.Geyer,USA
disruption of thalamocortical activity in psychedelicmodelsinanimalsFrancescArtigas,Spain
eeGpowerspectraandconnectivitychangesinpsychedelicanimalmodelsTomasPalenicek,CzechRepublic
neuroimaging and behavioral studies of cognitive andemotionaleffectsofserotonergichallucinogensinhumansFranzVollenweider,Switzerland
therapeuticdrugmonitoring,pharmacogeneticsandbrainimagingmethodsastoolsforimprovingpharmacotherapyChair: ChristophHiemke,GermanyCo-Chair: ChinBinEap,Switzerland
PharmacogeneticsforimprovingpharmacotherapiesChinBinEap,Switzerland
therapeutic drug monitoring for improving pharmaco-therapiesChristophHiemke,Germany
BrainimagingtechnologiesinpsychiatryGerhardtGründer,Germany
toolsforimprovingpharmacotherapyinpsychiatry:theopinionofaclinicianAndreasConca,Germany
theimportanceofpharmacovigilanceinpsychiatricinpatientpopulationsChair: StefanBleich,GermanyCo-Chair: AnastasiosKonstantinidis,Austria
Systematicpharmacovigilanceinpsychiatry–Isitnec-essary?SerminToto,Germany
Suicidalityduringantidepressanttreatmentinapsychia-tricinpatientpopulationSusanneStübner,Germany
restlesslegssyndromeinducedbypsychotropictreatmentKonstantinosPapageorgiou,Austria
Polypharmacyinpsychiatry–ariskfactorforadverseevents?AnastasiosKonstantinidis,Austria
pregnAncy, post pArtum And new Born: BAsic / clinicAl
recentadvancesinunderstandingandtreatingpsychiatricdisordersinpregnancyandpostpartumChair: SimoneVigod,CanadaCo-Chair: MeirSteiner,Canada
Investigating thephenotypicandgenotypicheterogene-ityofpostpartumdepressioninaninternationalperinatalpsychiatryconsortiumSamanthaMeltzer-Brody,USA
PreeclampsiaandriskofpostpartumpsychiatricepisodesTrineMunk-Olsen,Denmark
PregnancyoutcomesamongwomenusingantipsychoticdrugsSimoneVigod,Canada
transcranial magnetic stimulation for pregnant womenwithmajordepressivedisorderDeborahKim,USA
psychoneuroimmunology
diagnosticandprognosticstratificationofaffectivedisordersbasedoninflammationbiomarkersandimmunerelatedneurotransmitterpathwaysChair: AngelosHalaris,USACo-Chair: Aye-MuMyint,Germany
StratificationandoutcomepredictionofdepressedpatientsusingpanelsofinflammationbiomarkersAngelosHalaris,USA
Canplasmalevelsofkynureninesassistinthestratifica-tionofmooddisorders?Aye-MuMyint,Germany
Inflammation-induced disturbances of neurotransmitterprecursoraminoacidsandtheirpossibleroleasbiomark-ersindepressionBarbaraSperner-Unterweger,Austria
Biomarkerandtherapeuticpotentialoftheendocannabi-noidsysteminneuroinflammation-relatedpsychosesRafaelFranco,Spain
WFSBP 2015
16
Preliminary scientific Programme / symposia
psychopAthology
Psychobiologyofmen’smentalhealthChair: LeoSher,USACo-Chair: ZoltanRihmer,Hungary
theWFSBPmen’smentalHealthtaskForce:rationaleforaneuroendocrine-focusedapproachtomen’smentalhealthTimothyRice,USA
depressioninmen:ClinicalandphenomenologicalaspectsWolfgangRutz,Sweden
Suicideinmen:HormonalandneurobiologicalcorrelatesZoltanRihmer,Hungary
testosterone,violenceandhomicideLeoSher,USA
schizophreniA: BAsic / clinicAl
BiologicmarkersofcognitivedeficitsandnegativesymptomsinschizophreniaChair: NashN.Boutros,USACo-Chair: AdamWichniak,Poland
Cognition in schizophrenia: need for computationalmodelingtoidentifybiologicalmarkersAndreasHeinz,Germany
need for assessment batteries to examine cognition indeficitsyndromepatientsNashN.Boutros,USA
negativesymptomsinschizophrenia:mainissuesinthesearchforbiomarkersSilvanaGalderisi,Italy
quantitativeanalysisofneurophysiologicalsignalsasbi-ologicalmarkerofcognitivedeficitsandnegativesymp-tomsinschizophreniaAdamWichniak,Poland
CentralroleofglialcellsinthepathogenesisofschizophreniaChair: RobertSchwarcz,USACo-Chair: InaWeiner,Israel
microglia:Acommontargetfordiversedrugspreventingschizophrenia?InaWeiner,Israel
Prenatal elevation of the glia-derived neuromodulatorkynurenicacid:AnovelschizophreniamodelRobertSchwarcz,USA
ActivationofmicrogliaandastrocytesinschizophreniaislinkedtoincreasesinbraincytokinesKatarinaZavitsanou,Australia
Astrocytic dopamine modulates neuronal network andcognitivefunctionsintheprefrontalcortexJean-PierreMothet,France
Computational,cognitiveandpharmacologicalconnectomics:towardsunderstandingmechanismsofpsychosisChair: AlanAnticevic,USACo-Chair: DeannaBarch,USA
Integratingpharmacology,computationandconnectivitytounderstandschizophreniaonsetandprogressionAlanAnticevic,USA
Connectomicsofpsychosis:Crossdiagnosticsimilarities,differencesandrelationshipstordoCdimensionsDeannaBarch,USA
neural oscillations in meG-data: A translational per-spectivePeterUhlhaas,UnitedKingdom
elucidatingbiomarkersofriskforandprogressiontopsy-chosisusingneuroimagingTyroneCannon,USA
definingandre-definingtheboundariesofpsychoticdisordersusingneuroimagingChair: ChristosPantelis,AustraliaCo-Chair: NikolaosKoutsouleris,Germany
decomposing schizophrenia into intermediate imagingphenotypesidentifiedbymultiplesystemmappingHenrikWalter,Germany
IdentifyingneuroanatomicalsignaturesofschizophreniaphenotypesusingnovelimagingmethodsChristosDavatzikos,USA
Stratifying schizophrenia according to outcome usingmrI-basedpatternclassificationmethodsPaolaDazzan,UnitedKingdom
Commonalities and differences between schizophreniaand neurodegenerative disorders elucidated by neuro-imagingDennisVelakoulis,Australia
dysregulationoftyrosinetransportinfluencedopaminefunctionandcausecognitivedeficitsinschizophreniaChair: NikolaosVenizelos,SwedenCo-Chair: GeorgeE.Jaskiw,USA
Aberrant tyrosine transport in fibroblast from patientswithschizophreniaandbipolar-IdisordersNikolaosVenizelos,Sweden
17
WFSBP 2015
symposia / Preliminary scientific Programme
Aberrant tyrosine transport in fibroblast from patientswithschizophrenia–indicationofmaternalinheritanceLennaFlyckt,Sweden
tyrosinedepletionlowersinvivodoPAsynthesisinven-tralhippocampusGeorgeE.Jaskiw,USA
Acomparativegenomicmeta-analysisstudy focusedongenesandmechanismsinvolvedinaminoacidtransportinschizophrenicandbipolardisorderpatientsFragiskosKolisis,Greece
newinsightsofclinical,neurobiologicalandgeneticaspectsinmentalillnessChair: ThomasSchulze,GermanyCo-Chair: RyotaHashimoto,Japan
CurrentgeneticapproachestomajorpsychiatricdisordersThomasSchulze,Germany
recentadvancesinneuroinflammationrelevanttoschiz-ophreniatherapeuticsThomasWeickert,Australia
newgliaworldtopsychiatry:BrainfunctionandmentaldisordersManabuMakinodan,Japan
IntermediatephenotypestrategyfordiscoveringdiseaserelatedgenenetworkRyotaHashimoto,Japan
nitricoxide,glutamateandschizophrenia:newinsightsChair: DragosInta,GermanyCo-Chair: AndreasReif,Germany
nitricoxideandzinclevelsinlimbicregionsinpre-andpost-pubertal rats after neonatal lesions of the ventralhippocampusGonzaloFlores,Mexico
noS1-noS1AP interaction at the glutamatergic post-synapseasacandidatemechanismin thepathogenesisofschizophreniaAndreasReif,Germany
theglutamatereceptorcomplexinschizophreniapatho-genesisandtreatmentDavidBredt,USA
the islands of Calleja: the substrate for the glutama-te-nitricoxide-dopaminelinkinschizophrenia?DragosInta,Germany
Sleep,spindles,andschizophreniaChair: RobertMcCarley,USACo-Chair: GulioTononi,USA
SleepspindledeficitspointtothalamicreticularnucleusdysfunctioninschizophreniaGulioTononi,USA
optogeneticstudiesoftheroleofthethalamicreticularnucleusinspindles:ImplicationsforschizophreniaRobertMcCarley,USA
Sleepspindles,magneticresonancespectroscopyinthethalamusandcognitivefunctioningRetoHuber,Switzerland
Amathematicalmodelforasleepspindleanditsappli-cationtothequantificationofclozapineeffectsonsleepspindlesinschizophreniaPeriklisKtonas,Greece
theimpactoftobaccoandcannabisuseonpsychosisliabilityandillnesslongtermoutcome:epidemiologicalevidenceacrosseuropeandAustraliaChair: NikosC.Stefanis,GreeceCo-Chair: DavidCastle,Australia
tobaccoandcannabislongtermimpactonphysicalhe-althandclinicaloutcomesinschizophrenia.Isdisconti-nuationofsubstanceusefeasible?DavidCastle,Australia
Substanceusebringsforwardtheonsetofnon-affectivepsychosis: Potential biological mechanisms and clinicalimplicationsNikosC.Stefanis,Greece
How high potency cannabis (Sinsemilla/Skunk) use hasreshapedtheassociationbetweencannabisandpsychosisMartaDiForti,UnitedKingdom
environmentalexposuresandfamiliarriskforpsychosis:making senseofdifferential sensitivity to the effects ofcannabisJimvanOs,Netherlands
alpha4beta2-nicotinicacetylcholinereceptorsinschizophrenia:ImplicationsforsmokingcessationandtherapeuticsChair: IrinaEsterlis,USACo-Chair: EdenEvins,USA
nicotine dependence treatment in schizophrenia: evi-denceforeffectivenessofmaintenancepharmacotherapyEdenEvins,USA
WFSBP 2015
18
Preliminary scientific Programme / symposia
neuroscienceofnicotineaddictionvulnerabilityinschizo-phreniaAndrewChambers,USA
Invivoevidence forbeta2-nAChrupregulation insmo-kerswithschizophreniaIrinaEsterlis,USA
nicotinicCHrnA4genotypepredictsclinicaloutcomeinschizophreniaandneurolepticdrugtreatmentresponseGeorgWinterer,Germany
stimulAtion methods (ect, tms, vns, dBs)AdvancesinrepetitivetranscranialmagneticStimulation(rtmS)astreatmentforpsychiatricdisordersChair: DavidGorelick,USACo-Chair: ChristosTheleritos,Greece
Functional connectivity-based strategy of neuromodula-tionformajordepressionMotoakiNakamura,Japan
deeptranscranialmagneticstimulationinmajordepres-sion:FromanimalmodelstoclinicalapplicationYechielLevkovitz,Israel
Intermittentthetaburstprotocolforrestrictedandrepeti-tivebehavioronhighfunctionautisticspectrumdisorderMarcoMarcolin,Brazil
neuroplasticeffectsofstandardanddeeptmStreatmentasmeasuredbyeeGinindividualswithattention-deficithyperactivitydisorder(AdHd)AbrahamZangen,Israel
ClinicalapplicationsandtechnicalfoundationsoftranscranialdirectCurrentStimulation(tdCS),anon-invasivebrainstimulationtherapy,inpsychiatricdisordersChair: AndreBrunoni,BrazilCo-Chair: EmmanuelPoulet,France
tdCSinpsychiatry:mechanisticfoundationsandcurrentchallengesMichaelNitsche,Germany
tdCSforneuromodulationofdecision-making:Implica-tionsfortheaddictivebrainShirleyFecteau,Canada
ClinicalandbiologicalevidenceforusingtdCSinschizo-phreniaJeromeBrunelin,France
tdCSinmajordepressivedisorder:resultsfromrando-mizedclinicaltrialsandfollow-upstudiesAndreBrunoni,Brazil
IdentifyingthebiologicaltargetsoftreatmentresponsetoneuromodulationinresistantpsychiatricdisordersChair: ZafirisDaskalakis,Canada
neurophysiologicalandsymptomaticchangesinducedbymagneticseizuretherapyinschizophreniaZafirisDaskalakis,Canada
Cognitive,structuralandconnectivitychangesfromrepe-titive magnetic stimulation to the prefrontal cortex inschizophreniaAristotleVoineskos,Canada
eCt-Inducedchangesinfunctionalconnectivityintreat-mentresistantdepressionGeorgiosPetrides,USA
Changes in brain connectivity associated with medialforebrainbundledBSindepressionThomasSchlaepfer,Germany
recentresearchdatainelectroconvulsivetherapyandhowtheyinformstateoftheartclinicalpracticeChair: GeorgiosPetrides,USACo-Chair: DeclanMcLoughling,Ireland
theeFFeCt-deptrial:Bitemporalvs.high-doserightuni-lateralelectroconvulsivetherapyfordepressionDeclanMcLoughling,Ireland
Antidepressant efficacy of rul-ultra brief pulse eCt:datafromphaseIofthePrIdestudyCharlesKellner,USA
differentialresposetoeCtbetweenunipolarandbipolardepressionPascalSienaert,Belgium
KetaminepluseCt:Synergisticeffectsinthetreatmentofdepression?StylianiKaliora,USA
19
WFSBP 2015
symposia / Preliminary scientific Programme
thelatestinternationalfindingsregardingtmSfortreatingdepressionChair: PaulFitzgerald,AustraliaCo-Chair: MarkGeorge,USA
newdataonacutephasetreatments–dosingparadigms,improvingspeedofresponse,coildesignsPaulFitzgerald,Australia
HowdurablearetmSantidepressanteffects?newdataMarkDemitrack,USA
CombiningtmSwithCBtormedicationstoboostresponseMichaelThase,USA
thelatestadvancesinunderstandingtmSantidepressantneurobiologyShinsukeKito,Japan
suicide: BAsic / clinicAl
moleculardeterminantsofsuicideChair: GhanshyamPandey,USACo-Chair: JohnMann,USA
ImagingstudiesofsuicidalbehaviorneuralcircuitryJohnMann,USA
neuroinflammatory markers in suicide brain: Focus oncytokinereceptorsandtoll-likereceptorsGhanshyamPandey,USA
epigenomicbasis forastrocyteabnormalities insuicidalbehaviorGustavoTurecki,Canada
roleofmicrornAsintheetiologyandtreatmentofde-pressivedisorderandsuicideYogeshDwivedi,USA
translationalpsychiatryinmooddisordersandsuicideChair: JulioLicinio,AustraliaCo-Chair: PhilippeCourtet,France
ImagingandcognitivemarkersofsuicidalbehaviorFabriceJollant,Canada
omicspredictorsofsuicidalbehaviourEnriqueBacaGarcia,Spain
theroleofneuroinflammationandimmunityonsuicidalityPhilippeCourtet,France
Serotonin and endocannabinoid system in mood disor-ders:AnimalandclinicalstudiesGabriellaGobbi,Canada
WFSBP 2015
20
Preliminary scientific Programme / Workshops
WorKSHoPS
BipolAr disorders: BAsic / clinicAl
lithiumphobia:Scienceorsuperstition?Chair: DigvijayGoel,NewZealandCo-Chair: MohanIsaac,Australia
lithium:Scienceorsuperstition?DigvijayGoel,NewZealand
lithium:themagicionShaileshKumar,NewZealand
lithiumvs.sodiumvalproate:understandingthedilemmaRajeshNagpal,India
lithium:thewayforwardsMohanIsaac,Australia
mooddisordersandbipolarspectrum:HowtogetoverdiagnosticproblemsChair: GiuseppeTavormina,ItalyCo-Chair: NicolasZdanowicz,Belgium
Bipolarityduringtheadolescence:limitsoftheconceptNicolasZdanowicz,Belgium
depressionandworkrelatedstressproblemsMarilisaAmorosi,Italy
depressivedisordersandresilienceSandroElisei,Italy
evaluation of cases reports of bipolar spectrum mixedstates:Adiagnostic-therapeuticapproachGiuseppeTavormina,Italy
AlatinAmericancontributiontobipolardisordersChair: EugenioVargasPena,ParaguayCo-Chair: GuillermoDorado,Argentina
KraepelinmodelinbipolardisordersJaimeVengoechea,Colombia
AddictivedisordersandbipolarityGuillermoDorado,Argentina
BipolarIIdisordersandsuddenepisodicdepressionEugenioVargasPena,Paraguay
Commentsonbrain-SPeCtandbipolardisordersEnriqueGalli,Peru
childhood & Adolescent disorders: BAsic / clinicAl
evaluationandmanagementofyouthwithautismspectrumdisordersandco-morbidbehavioralandneurologicsymptomsChair: AdelaideRobb,USACo-Chair: PeterDaniolos,USA
multidisciplanaryteamevaluationofyouthwithautismPeterDaniolos,USA
treatmentofdisruptivebehaviorandaggressioninautismAdelaideRobb,USA
recognitionandmanagementofepilepsyinautismWilliamGaillard,USA
use of telehealth to increase accessibility of evidence-basedinterventionforchildrenwithPddToddKopelman,USA
cognitive neuroscience
neurocognitiveandfunctionalimpairmentinmooddisordersChair: SagarParikh,CanadaCo-Chair: RoumenMilev,Canada
neurocognitivedeficitsinmooddisorders:Biologicalun-derpinningsBenicioFrey,Canada
Clinicalassessmentofneurocognition:thebasisforim-provedclinicaloutcomesMichaelBerk,Australia
neurocognitiveand functionaloutcomes inbipolardis-ordersSergeBeaulieu,Canada
neurocognitiveandfunctionaloutcomesindepressionArunRavindran,Canada
Patient’sresponsetotreatment:AneurobiologicalapproachChair: JorgeTellez-Vargas,ColombiaCo-Chair: PolicarpoRebolledo,Chile
InflammatoryandmetabolicdysregulationaspredictorofantidepressantresponseJorgeTellez-Vargas,Colombia
Seekingrelief:theactivationofmotivationalandrewardcircuitsRubyCastilla-Puentes,USA
PharmacogeneticsstudiesinlatinAmericaHernanSilva,Chile
GeneticandpsychiatricdiagnosisVeronicaLarach,Chile
21
WFSBP 2015
Workshops / Preliminary scientific Programme
dementiA
developmentofbiologicalmarkersfordifferentialdiagnosisofdementiainphysiologicalandbiochemicalstrategiesChair: ToshihisaTanaka,JapanCo-Chair: FernandoMaestu,Spain
magnetoencephalographyfordiagnoseandevaluationofdementiaFernandoFernando,Spain
FunctionalconnectivityineeGfordiagnosisofAlzheimerdiseaseLeonidesCanuet,Spain
Screeningofcognitiveimpairmentanddiagnosisofde-mentiaKatsuyaUrakami,Japan
CSFbiomarkersindifferentialdiagnosisofdementiaToshihisaTanaka,Japan
depression: BAsic / clinicAl
roleofaldosteroneandmineralocorticoidreceptorfunctioninemotion-regulationChair: HaraldMurck,USACo-Chair: AlanKimJohnson,USA
AldosteroneinstressrelateddepressionmodelsMikeFranklin,UnitedKingdom
Sodiumdeficiencyandmood:thebrainrenin-angioten-sin-aldosteronesysteminthecravingforsaltandinan-hedoniaAlanKimJohnson,USA
AldosteroneandmineralocorticoidfunctionaspredictorsofantidepressantresponseHaraldMurck,USA
theroleofmineralocorticoidreceptorsinemotionalre-gulationinborderlinepersonalitydisorderKatjaWingenfeld,Germany
taskforcerecommendationsforthemanagementofcomorbidityinmajordepressivedisorderandbipolardisorderChair: RogerMcIntyre,CanadaCo-Chair: RoumenMilev,Canada
Generalprinciplesofmanagingcomorbidity:AfocusonmedicalcomorbidityRogerMcIntyre,Canada
managementofpatientswithcomorbidmoodandanxi-etydisordersAyalSchaffer,Canada
managingsubstanceuseinmooddisordersSergeBeaulieu,Canada
treating bipolar disorder in the real world integratingcomorbidityintotreatmentdecisionsAllanYoung,UnitedKingdom
neurophysiology
transcranialmagneticstimulationstudiesofneurophysiology,neuroplasticity,andneurocognitioninpsychiatricdisordersChair: PaulCroarkin,USACo-Chair: ZafirisDaskalakis,Canada
overviewoftranscranialmagneticstimulationstudiesinseverepsychiatricdisordersZafirisDaskalakis,Canada
tmSstudiesofborderlinepersonalitydisorderandchronicpainShirleneSampson,USA
rtmSstudiesofneurocognitioninschizophreniaAristotleVoineskos,Canada
theneurochemistryoftmS:magnetic resonance spec-troscopystudiesJohnDPort,USA
oBsessive-compulsive disorders: BAsic / clinicAl
Biologicalapproachestowardclarifyingheterogeneitiesofobsessive-compulsivedisorderChair: TomohiroNakao,JapanCo-Chair: HisatoMatsunaga,Japan
Altered frontostriatal connectivity in obsessive-compul-sivedisorderTakashiNakamae,Japan
neurobiologicalheterogeneitiesofoCdTomohiroNakao,Japan
Cross-culturalaspectsofsymptomdimensionofoCdHisatoMatsunaga,Japan
does the neurobiology of obsessions and compulsionsdiffer?DamiaanDenys,TheNetherlands
WFSBP 2015
22
Preliminary scientific Programme / Workshops
posttrAumAtic stress: BAsic / clinicAl
InteractionbetweenneurobiologicalandethnoculturalfactorsinPtSdtreatmentresponse,recoveryandresilience.Istherealink?Chair: SorayaSeedat,SouthAfricaCo-Chair: MushtaqMargoob,India
Contributionofethnocultural,geneticandbiologicalfac-torstoincreasingordecreasingPtSdtreatmentresponse–anAsianexperienceMushtaqMargoob,India
Contributionofethnocultural,geneticandbiologicalfac-torstoincreasingordecreasingaperson’sriskfordevel-opingPtSdonceheorshehasbeenexposedtotrauma–anAfricanexperienceSorayaSeedat,SouthAfrica
AmodelofsuicidalbehavioramongimmigrantswithPtSdLeoSher,USA
BdnFgenetics,serumBdnF,andethnicity:ImplicationsforinterveninginPtSdSorayaSeedat,SouthAfrica
schizophreniA: BAsic / clinicAl
metabolicdisturbancesinschizophrenia:epidemiology,pathophysiologyandantipsychotics–towardsclinicalapplicationofgeneticriskmodelsandnewtreatmentstrategiesChair: WiepkeCahn,TheNetherlandsCo-Chair: BjørnH.Ebdrup,Denmark
Antipsychotic-associated dysmetabolism: Glucometabo-lichormones,cardiovascularriskmarkersandpotentialphysiologicalbenefitsofglucagon-likepeptide-1receptoragonisttreatmentBjørnH.Ebdrup,Denmark
nationwidestudiesofdiabetesinpsychiatricpopulationsRenéE.Nielsen,Denmark
Antipsychotic-inducedglucosedisturbances:FrommicetomenMargaretHahn,Canada
GWAS in antipsychotic-induced weight gain dissectingtheCAtIesampleDanielJ.Müller,Canada
treatmentofschizophrenia:PersonalizedtailoringtomeetpatientsneedsChair: KonstantinosFountoulakis,GreeceCo-Chair: CyrilHoschl,CzechRepublic
Antipsychotics:differencesandspecificityAlessandroSerretti,Italy
InformationtechnologyinthemanagementofschizophreniaCyrilHoschl,CzechRepublic
Computer-assistedtreatmentpathwayforschizophrenia:developmentandfirstresultsinover200patientsGeorgJuckel,Germany
theoptimizationeffectinschizophrenia:Whyweseedif-ferentthingsineverydayclinicalpracticeKonstantinosFountoulakis,Greece
suicide: BAsic / clinicAl
PathwaysassociatingstresstotheneurobiologyofsuicideChair: LeoSher,USACo-Chair: JorgeOspina-Duque,Colombia
Aneurobiological stress-diathesismodelof suicidalbe-haviorLeoSher,USA
Stress and suicide: the role of the hypothalamic-pitu-itary-adrenalaxisM.DoloresBraquehais,Spain
relationbetweenstress,serotonin,andsuicideMushtaqMargoob,India
oxytocininsuicidalbehaviorJussiJokinen,Sweden
SuicideandbehavioraladdictioninKorea:SearchingforthebiopsychosocialbasisinthefastchangingsocietyChair: ChangUkLee,RepublicofKoreaCo-Chair: HanYongJung,RepublicofKorea
Crossculturaldifferences in theattitudetowardsuicide:multi-countriescomparisonstudyYongMinAhn,RepublicofKorea
PostventionprogramforsuicideattemptersinSeoulJong-WooPaik,RepublicofKorea
GeneticneuroimagingstudytofindtheneurobiologyofdepressivedisordersByungjooHam,RepublicofKorea
neurobiologyofimpulsivebehaviorsandbehavioralad-dictionsDai-JinKim,RepublicofKorea
23
WFSBP 2015
Topics
The scientific programme of the WFSBP 2015 Congress will cover the following topics, within each topic the track may be Basic, Clinical, Interface or Conceptual:
1. Addictive Disorders2. Antidepressants: Basic / Clinical3. Antipsychotics: Basic / Clinical4. Anxiety Disorders: Basic / Clinical5. Anxiolytics: Basic / Clinical6. Bipolar Disorders: Basic / Clinical7. Childhood & Adolescent Disorders: Basic / Clinical8. Cognitive Neuroscience9. Dementia: Basic / Clinical10. Depression: Basic / Clinical11. Eating Disorders: Basic / Clinical12. Emergency Psychiatry13. Epidemiology14. Ethics and Psychiatry15. Forensic Psychiatry16. Genetics17. Hypnotics: Basic / Clinical18. Liaison Psychiatry19. Mental Retardation or Chromosomal Aberrations:
Basic / Clinical20. Molecular Neurobiology21. Mood Stabilisers: Basic / Clinical22. Neuropathology23. Neuroimaging: Genetic, Functional, Structural
24. Neurophysiology25. Obsessive-Compulsive Disorders: Basic / Clinical26. Oncopsychiatry27. Pain: Basic / Clinical28. Panic Disorders: Basic / Clinical29. Personality Disorders: Basic / Clinical30. Pharmacoeconomics31. Pharmacogenetics32. Pharmacology33. Posttraumatic Stress: Basic / Clinical34. Pregnancy, post partum and new born: Basic / Clinical35. Premenstrual Syndrome: Basic / Clinical36. Psychogeriatrics37. Psychoneuroimmunology38. Psychopathology39. Psychosurgery40. Schizophrenia: Basic / Clinical41. Sexual Disorders: Basic / Clinical42. Sleep Disorders: Basic / Clinical43. Somatoform Disorders: Basic / Clinical44. Stimulation Methods (ECT, TMS, VNS, DBS)45. Stress: Basic / Clinical46. Suicide: Basic / Clinical47. Violence: Basic / Clinical
WFSBP 2015
24
Call for Abstracts for free Communications and Posters
deadline for abstract submission: 10 december 2014notificationofacceptance/rejection:march2015
Authors of Free Communications or Posters are hereby kindly invited to submit an abstract for contributions to the WSFBP 2015 Congress by using the online submission form on the congress website www.wfsbp-congress.org. Please note that online submission is mandatory. Free Communications and Posters submitted individually and accepted by the International Scientific Programme Committee will be grouped by category topics into the-matic sessions in order to promote communication among the presenters and participants and to allow for inspiring discussions.
FreeCommunICAtIonSThe Free Communications will be selected by the Internati-onal Scientific Programme Committee after abstract sub-missions have been reviewed. The 90-minutes sessions will be grouped by topics and chaired by selected specialists. The time slot for a single presentation in a Free Communi-cation session is 15 minutes including discussion time. only1FreeCommunicationabstractmaybesubmittedperauthor.
PoSterSEach accepted poster will be exhibited at the WFSBP 2015 Athens Congress in the Muses Foyer of the Megaron Athens International Conference Centre. The best posters will be grouped into thematic Guided Poster Tours chaired by re-nowned specialists. The Guided Poster Tours will give the authors the opportunity to present their findings and dis-cuss them with the audience. A maximum of 4 postersabstractsmaybesubmittedperauthor.The congress will deliver WFSBP young InvestigatorAwards for the five best posters. Please refer to page 26 for further information.
Please note that accepted abstracts will be published only after completed registration and payment of the congress registration fee. The acceptance of submitted abstracts si-multaneously results in binding registration of the speaker to attend the conference. theregistrationfeemustbepaid immediately after receiving the abstract acceptance, latestuntil1April2015. Authors who have not settled the regis-tration fee until that date will be omitted from the scientific programme. onsiteregistrationforpresentingauthorsisnotpossible.
GuIdelIneSFortHePrePArAtIonoFABStrACtSPlease submit your abstracts online and in English, the offi-cial language of the WFSBP Congress 2015.
U Please choose a title that clearly indicates the content of the contribution.
U Please avoid abbreviations in the title. Abbreviations may be used in the text if they are defined when used first.
U The author’s name (full first name, family name) and place of work (institution, city, country) should be given. Degrees, titles, street addresses, and acknowledgements of support should be omitted, however.
U The abstract submission must be complete.U Please choose a topic from the topic list, page 23.U The text of the abstract should briefly state: objectives
(indicate the purpose of the study or the hypothesis that was tested), methods (include the setting for the study, the subjects, the diagnosis or intervention, and the type of statistical analysis), results(present as clearly as possi-ble the outcome of the study and statistical significance if appropriate) and Conclusions (briefly discuss the data and emphasise the significance of the results). References need to be given in the text.
U The length of your abstract is limited to a maximum of 300 words.
U Please ensure that the abstract does not contain spelling, grammar or scientific errors, as it will be reproduced ex-actly as submitted. Submitted abstracts will not be edited in any way. If the abstract does not fulfil the necessary requirements it cannot be published.
U A disclosure of the existence of any significant financial interest or other affiliations with a funding organisation or with a commercial supporter of the session and / or provi-der of commercial services is required.
U All abstracts will be published online in the scientific pro-gramme of the WFSBP Congress from April 2015.
U only1FreeCommunicationAbstractmaybesubmit-tedperauthor.
U Amaximumof4postersmaybesubmittedbyeachauthor.
25
WFSBP 2015
format Descriptions of the scientific sessions
oPenInGleCtureThe Opening Lecture will be held during the Opening Ce-remony on 14 June 2015.
PlenAryleCtureSPlenary Lectures are 45-minute sessions held by renowned experts. The speakers have been chosen from among the most prominent researchers in the respective field.
SymPoSIASymposia are selected, covering basic, clinical, interface and conceptual topics of Biological Psychiatry. Symposia will be organised and chaired by the experts whose propo-sals are accepted by the International Scientific Programme Committee.
WorKSHoPSWorkshops are highly interactive sessions with an educatio-nal focus. This format is especially designed to give specific regions a platform for presentation and networking.
deBAteSDebates are intended to offer a platform for a lively, yet balanced discussion on controversial issues. A moderator (chairperson) and two speakers (one proponent and one opponent) will state their opinions on different subjects.
WFSBPtreAtmentGuIdelIneSTreatment Guidelines Sessions are 90-minute sessions with an educational focus. They centre on the WFSBP Treatment Guidelines and include brief presentations by individual pa-nel members, followed by lively and informative discussion. This session type provides for substantial audience participa-tion and should be highly interactive.
FreeCommunICAtIonSAuthors will be invited to submit abstracts on their latest research findings. All submitted abstracts will be reviewed and the best will be selected and allocated to Free Commu-nication Sessions.
GuIdedPoStertourSA whole range of highly interesting papers on new research findings and / or major research efforts are expected to be submitted as posters. As many posters will probably be sub-mitted by young investigators, the Local Organising Com-mittee will arrange Guided Poster Tours to give the authors the opportunity to present these findings and discuss them with the audience.
CmeACCredItAtIonAn application will be made to the EACCME® for CME accreditation of this event.
WFSBP 2015
26
WfsBP Awards
The following WFSBP Awards will be delivered and presen-ted during the 12th World Congress of Biological Psychiatry 2015 in Athens.
U WFSBP lifetime Achievement Award in BiologicalPsychiatry
The WFSBP Lifetime Achievement Award in Biologi-cal Psychiatry is intended for senior research scientists (MD, PhD or equivalent) whose lifework has sig-nificantly influenced today‘s field of biological psychi-atry. This award is open to members and non-mem-bers of the WFSBP. It consists of a monetary award of EUR 1,000.
U WFSBPAwardforScientificexcellenceoftheWFSBPHost
The WFSBP Award for Scientific Excellence of the WFSBP Host is dedicated to an outstanding resear-cher in the field of Biological Psychiatry originating from the host country of the World Congress of Biolo-gical Psychiatry. This award consists of a monetary award of EUR 1,000.
U WFSBPresearchPrize The WFSBP Research Prize is intended for WFSBP
members (MD, PhD or equivalent) whose current sci-entific work has had an important impact in the field of clinical and/or basic research in the area of biologi-cal psychiatry. This prize consists of a monetary award of EUR 1,000.
U WFSBPAwardforexcellenceineducation The WFSBP Award for Excellence in Education is to
acknowledge outstanding and innovative education in biological psychiatry including the implementa tion of new interactive media. The WFSBP Education prize is open to all WFSBP members who have improved the education in all fields of Psychiatry. This award consists of a monetary award of EUR 1,000.
Please note that presenting authors must register and attend the meeting to be eligible for any of these awards.
Applications must be sent by e-mail to the congress and exhibition office:
Hamburg OfficeHanser & Co GmbHZum Ehrenhain 34 Phone: +49 – 40 – 670 88 20Fax: +49 – 40 – 670 32 83Email: [email protected]
by10december2014 and should include a short summary of the work and a brief CV. The letter should outline the main professional activities and provide key peer review pu-blications. Prizes will be announced during the Opening Ceremony.
U WFSBPyoungInvestigatorAwardsforthefivebestposters(under40year-old)
An application for the Young Investigator Award is not necessary. All posters will be evaluated at the con-gress. The awards will go to those presentations that not only provide evidence of innovative research, but which are also well presented.
Please note that presenting authors must register and attend the meeting to be eligible for this award. Poster prizes will be delivered during the Closing Ceremony.
27
WFSBP 2015
Congress Information
Please register online for the WFSBP 2015 Athens Congress. Simply complete the registration form available on the Inter-net: www.wfsbp-congress.orgor make use of the registration form enclosed at the end of this document.
PAymentWhen registering for the WFSBP 2015 Congress in Athens, please arrange for payment of the registration fee. All pay-ments should be made in EURO. You may choose between two modes of payment: credit card payment or bank transfer. Especially for payment made from outside Germany where the congress office is based, we strongly recommend credit card payments as charges for bank transfers may apply twice, once in the country of origin and a second time in Germany.
Please choose one mode of payment: Creditcard: AMEX, Eurocard / Mastercard or VISA orBanktransfertothecongressbankaccount:CPO HANSER SERVICE w / WFSBP ZB 2015HSH Nordbank AG / Bank Code: 210 500 00Account Number: 1001 2458 74BIC: HSHNDEHH / IBAN: DE06 2105 0000 1000 2458 74
ConFIrmAtIonUpon receipt of the registration and the corresponding pay-ment, the congress office will send a confirmation form which also serves as an invoice. Please show this confirma-tion of registration at the congress counter when picking up your congress materials.
CAnCellAtIonoFConGreSSPArtICIPAtIonNotice of cancellation should be sent in writing only to the Congress Office CPO HANSER SERVICE. In case of cancel-lation by 28 January 2015 the payment will be refunded, minus a handling charge of 25%. No refund will be made after 28 January 2015.
on-SItereGIStrAtIonAFter2june2015On-site registration will be possible but we recommend to register well in advance. Participants who wish to register on-site are advised to arrive early. On-site registration does not entitle participants to receive a delegate bag. On-site regis-tration will be handled on a first-come, first-served basis, priority will be given to pre-registered delegates.
Registration and payment received
Early registration by 28 January 2015
EUR
Late registration by 2 June 2015
EUR
On-site registration after 2 June 2015
EUR
WFSBP Members 530 630 730
Non-Members 630 730 830
Greek Psychiatrists*** 480 570 660
Participants from Low-Income Countries* 290 390 490
Trainees** 290 390 490
Greek Students** 170 230 290
Congress Registration for the 12th World Congress of Biological Psychiatry is available via the congress website at www.wfsbp-congress.org.
* According to the Low-Income-Countries defined by the world bank. Please see the list on the WFSBP website www.wfsbp-congress.org** Trainee / Student status must be confirmed by certificate in writing by head of department and is applicable only for participants born after
1 Jan 1980. Please send your certificate by email or fax to: Hanser & Co GmbH, Fax: +49 – 40 –670 32 83, Email: [email protected]*** Psychiatrists resident in Greece.
WFSBP 2015
28
General Information
ConGreSSVenueMegaron Athens International Conference CentreLeoforos Vasilissis Sofias and Kokkali 1Athens 115 21, Greece
ConGreSSreGIStrAtIondeSKThe congress counter will be located in the Mitropoulos Foyer, on the right hand side of entrance B of Megaron Athens International Conference Centre, which is the main entrance area for the WFSBP 2015 Congress.
Preliminaryopeninghours
Sunday, 14 June 2015 12:00 – 19:00
Monday, 15 June 2015 07:30 – 18:30
Tuesday, 16 June 2015 08:00 – 18:30
Wednesday, 17 June 2015 08:00 – 18:30
Thursday, 18 June 2015 08:00 – 17:00
ConGreSSAndexHIBItIonoFFICe
Hamburg OfficeHanser & Co GmbHZum Ehrenhain 34 22885 Barsbüttel, GermanyPhone: +49 – 40 – 670 88 20Fax: +49 – 40 – 670 32 83Email: [email protected]
PoSterexHIBItIonPosters will be displayed from Monday, 15 June to Thurs-day, 18 June 2015 in the Muses Foyer nearby the technical exhibition. Each congress day there will be one Guided Po-ster Tour with the best posters only. The posters selected for the Guided Poster Tour will be displayed in a special area of the congress centre. During the review of the abstracts which is done by the Local Organising Committee, the re-viewers will indicate the candidates for the Guided Poster Tours. All other posters will be displayed for one entire con-gress day and grouped according to topics.
Information regarding poster format, set-up and dismant-ling will be sent to the authors along with their notification of acceptance.
teCHnICAlexHIBItIonThe WFSBP Congress 2015 will be accompanied by a ma-jor technical exhibition taking place in the Muses Foyer of the Megaron Athens International Conference Centre. Po-tential exhibitors can request an exhibition/sponsoring bro-chure from the exhibition office CPO HANSER SERVICE.Email: [email protected]
Preliminaryopeninghours
Monday, 15 June 2015 09:00 – 17:00
Tuesday, 16 June 2015 09:00 – 17:00
Wednesday, 17 June 2015 09:00 – 17:00
ConGreSSInFormAtIonSyStem/CoConGreSSonlIne®
The web based Congress Information System CO CON-GRESS ONLINE® has been installed atwww.wfsbp-congress.org
Prior to the congress, CO CONGRESS ONLINE® will provi-de information on:U Preparation of the congressU List of topicsU Call for abstractsU Invited speakers and invited conveners of symposiaU Preliminary scientific programmeU Accepted abstractsU List of participants (who is who)U List of exhibitorsU Information about the main sponsorsU AthensU Hotel accommodationU Travel to AthensU Special newsU Private mailbox
In due time, the final programme will be published on CO CONGRESS ONLINE® which enables each participant to create her / his personal congress programme schedule. CO CONGRESS ONLINE® offers an extensive congress service.
29
WFSBP 2015
General Information
FInAlProGrAmmeThe final programme and abstracts will be published on the Internet at www.wfsbp-congress.org prior to the congress.
WFSBP2015ConGreSSAPPmoBIleThe WFSBP 2015 Congress App is free for congress partici-pants and provides iPhone/iPad, android and other smart-phone users at WFSBP 2015 in Athens with on-the-go ac-cess to the congress. The most up-to-date congress schedule is available at the fingertips during the congress. Available for download prior to WFSBP 2015 – powered by GLOBIT’s acclaimed CONGRESS MOBILE software.
ConGreSSlAnGuAGeThe official language of the WFSBP Congress 2015 is English. Simultaneous translation will not be provided.
letteroFInVItAtIonThe congress will be pleased to send a formal letter of invi-tation to any registered delegate requesting one. It is under-stood that such an invitation is intended to help potential delegates to raise funds or to obtain a visa. This does not imply a commitment from the congress to provide any fi-nancial support. Letters of invitation may be requested from the congress office.
VISAThe entry formalities for Greece vary according to the country of origin. The Ministry of Foreign Affairs of Greece advises on its website a list of countries that do not and that do require a visa to enter the country. Please visit the web-site www.mfa.gr.
oFFICIAlItAlIAnAGenCyForItaliandelegatesonly:AIM Group International – AIM Education S.r.l. has been appointed as the Italian Official Agency for AIFA submissi-on. Italian pharmaceutical companies which require spe-cific authorisation from the Italian Health Ministry are ad-vised to contact:
AIM Group International – AIM Education S.r.l.Raffaella Figerio / Cristina GhidoliVia G. Ripamonti, 129 l 20141 Milan, ItalyPhone: +39 – 02 – 56601.288/360Fax: +39 – 02 – 70048585Email: [email protected]
InSurAnCePlease notice that the congress fee does not include insu-rance. All participants should arrange for their own insu-rance. Health and accident insurance is strongly recommen-ded and will need to be purchased in the country of origin.
ForCemAjeureFor reasons beyond its control (such as war, strikes, lock-outs, riots or any such civil disturbances, any natural di-saster, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circum-stance of whatsoever nature beyond control) that have an impact on the arrangements, timetables or planning of the 12th World Congress of Biological Psychiatry (WFSBP 2015) and its corresponding activities in Athens, WFSBP has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.
CurrenCyThe Greek Currency is Euro (€). The euro is freely converti-ble on world currency markets. The exchange rate fluctu-ates daily depending on the money market.
ClImAteThe city of Athens is located in a Mediterranean climate. The average temperature for the month of June is 28 °C / 82 °F and it can drop down to 20 °C / 68 °F. The sun shines 13 hours a day. The sun’s rays are strong and it is recommended to use sun-cream and to wear a hat and sunglasses. A bottle of water should be taken with you every time you go outside to keep yourself appropriately hydrated. In average it rains 4 days in the month of June.
AIrPortThe Athens-Eleftherios Venizelos Airport (ATH) is the inter-national airport of the city Athens. It is named after the pre-mier Eleftherios Venizelos (1864 – 1936) and is the biggest and most important airport of Greece. The airport functions as an intersection for the Middle East and the Balkans. More than 13 million travelers transfer via the ATH yearly. It is 25 kilometers away from the city center and part of the commune Spata.
WFSBP 2015
30
General Information
trAnSPortBetWeenAIrPortAndCIty/CItyAndmeGAronAtHenSInternAtIonAlConFerenCeCentreThe metro M3 takes about 30 minutes from the airport to the Meragon Athens International Conference Centre (me-tro station “Megaron Moussikis” on metro line 3 (blue line). Please visit the website www.ametro.gr for more informati-on about the prices and departure times.
HouSInGAndloCAlAGenCyFor the 12th WFSBP Congress, the hotel accommodation and organised tours will be realised by our on-site partner company AFEA.
AFeAS.A.39-41 Lykavittou Str. •10672 Athens, Greece Email: [email protected]: +30 – 210 3668800Contact: Martha Kornarou
PleasebookyourhotelandtoursonlinewithAFeA.As the official housing agency for WFSBP AFEA has secured a variety of hotels that range from luxurious to more stan-dard accommodations. Whether in downtown Athens, or in the direct surrounding of the Megaron International Conference Centre, there is a hotel for every taste, budget and need. AFEA has negotiated special rates for congress delegates. As June is a high season in Athens we kindly ad-vise all delegates and speakers to make their bookings well in advance.
All hotels are available online via congress website:www.wfsbp-congress.org
CItyoFAtHenSLocated in the very southeast of Europe, Greece – ‚Hellas‘ – is one of the oldest cultural spot within Europe. With a total population of around 11,3 million people, more than a third – 4 million people – live in Athens, the Capital. Athens is located in the Attica prefecture, in particular in the Attica basin, which is framed by Mount Aegaleo, Mount Parnitha, Mount Penteli and Mount Hymettos.
Athens has been founded more than 5,000 years ago and therefore is – unchallenged – the oldest and most ancient capital in Europe. But not only is the age a measure. Nowa-days Athens is a very special spot in the world where ancient culture meets the challenges and advantages of todays life.
This was proved very successfully by the Olympic summer games in 2004. Athens has come up with infrastructure, facilities and services that meet global standards – so far the 12th World Congress of Biological Psychiatry will become another successful global event in a global environment.
Next to the most famous sites of Athens, such as the Acro-polis, the National Archaeological Museium of Athens, the Museum of the Acropolis, the Plaka area, also known as the god´s neighborhood. Athens is very famous for the attic light, a unique yellow golden light which has been descri-bed since ancient times.
Also in scientific terms, Greece and especially Athens have much going for: Nine universities are located in Athens. In the 20th century, two Nobel Prize of Literature awardees were born in Greece: Odysseas Elytis (1911-1996), recei-ved the prize in 1979 – and Giorgos Seferis (1900-1971), who was the awardee of 1963.
Attend the 12th Congress of the World Federation of Biolo-gical Psychiatry and see for yourself what else Athens and Greece have to offer.
Dates to remember
10 December 2014 Abstract submission for posters and free communications
28 January 2015 Deadline early bird registration
14 June 2015 Opening Ceremony, and Reception and Networking Event
www.wfsbp-congress.org